Icariin as a Metabolic Regulator of Bone Marrow Mesenchymal Stem Cells: Mechanisms and Therapeutic Implications to Bone Homeostasis.

Epimedium and its principal bioactive flavonoid, Icariin (ICA), are recognized as significant regulators of bone metabolism. ICA is well-documented for its ability to enhance osteogenesis and suppress osteoclastogenesis, yet its capacity to influence cellular metabolic pathways is a burgeoning field of investigation. The differentiation of bone marrow mesenchymal stem cells (BMSC) into either osteogenic or adipogenic lineages is intricately associated with intrinsic metabolic alterations, the dysregulation of which is a pivotal factor in the pathogenesis of osteoporosis. This review, conducted following a systematic literature search and quality assessment utilizing Joanna Briggs Institute (JBI) tools, examines the potential of ICA to modulate the osteogenic-adipogenic equilibrium of BMSC. Given that much of the extant evidence concerning direct metabolic reprogramming is indirect, we integrate insights from recent molecular studies to propose mechanisms by which ICA may interact with critical BMSC pathways, particularly glycolysis and fatty acid metabolism. Ultimately, we assess the therapeutic prospects of modulating BMSC metabolism with ICA, and we identify prospective directions for its clinical application in the management of bone disorders.